Financials

News Discussions Technicals Seasonals

BDRX fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to Biodexa Pharmaceuticals plc operating, investing, and financing activities

BDRX free cash flow for H1 24 is -5.96 M USD. For 2023, BDRX free cash flow was -8.44 M USD and operating cash flow was -8.41 M USD.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: USD

TTM

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—